A bispecific antibody is described comprising a first antigen binding arm that binds FRa receptor and a second antigen-binding arm that binds CD3, wherein: a) the first antigen-binding arm (A) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), A- VHCDR1, A-VHCDR2 and A- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 1, 2 and 3 respectively three light chain complementarity determining regions (CDRs), A- VLCDR1, A-VLCDR2 and A- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 4, 5 and 6 respectively b) the second antigen-binding arm (B) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), B- VHCDR1, B-VHCDR2 and B- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 7, 8 and 9 respectively three light chain complementarity determining regions (CDRs), B- VLCDR1, B-VLCDR2 and B- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 10, 11 and 12 respectively. Furthermore, the pharmaceutical composition comprising said bispecific antibody and its pharmaceutical use are described.